Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Polidocanol
Drug ID BADD_D01792
Description Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Indications and Usage Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
Marketing Status Prescription
ATC Code C05BB02
DrugBank ID DB06811
KEGG ID D01993
MeSH ID D000077423
PubChem ID 656641
TTD Drug ID D05ZPL
NDC Product Code 52919-021; 60635-107; 67850-141; 67850-140; 60635-118; 60635-111; 52919-024; 52919-022; 46783-221; 46783-121; 72969-060; 60635-133
Synonyms Polidocanol | Polidocanols | Laureth 9 | Laureth-9 | Lubrol 12A9 | Laureth-7 | Laureth 7 | Polyethylene Glycol-7-lauryl Ether | Ether, Polyethylene Glycol-7-lauryl | Polyethylene Glycol 7 lauryl Ether | Polyethylene Glycol-7-lauryl Ethers | Lauromacrogol | Lauromacrogols | Polyoxyethylene Lauryl Ether | Ether, Polyoxyethylene Lauryl | Polyoxyethylene Lauryl Ethers | Thesit | Nonaethylene Glycol Monododecyl Ether | Nonaethyleneglycol Monododecyl Ether | Ether, Nonaethyleneglycol Monododecyl | Monododecyl Ether, Nonaethyleneglycol | Nonaethyleneglycol Monododecyl Ethers | alpha-Dodecyl-omega-hydroxypoly(oxy-1,2ethanediyl) | Polyoxyethylene-4-dodecyl Ether | Ether, Polyoxyethylene-4-dodecyl | Polyoxyethylene 4 dodecyl Ether | Polyoxyethylenedodecyl Ether | Polyoxyethylenedodecyl Ethers | Tetraethyleneglycol Lauryl Ether | Ether, Tetraethyleneglycol Lauryl | Lauryl Ether, Tetraethyleneglycol | Tetraethyleneglycol Lauryl Ethers | Laureth-4 | Laureth 4 | Polyoxyethylene(4) Lauryl Ether | Lauromacrogol 400 | Polyethylene Glycol Monododecyl Ether | Brij 30 | Brij-30 | Brij30 | Tetraethylene Glycol Dodecyl Ether | Laureth | Laureths | Dodecyl Ethyleneglycol Monoether | Dodecyl Ethyleneglycol Monoethers | Ethyleneglycol Monoether, Dodecyl | Monoether, Dodecyl Ethyleneglycol | Laureth-1 | Laureth 1 | Aethoxysclerol | Ethoxysclerol | Aethoxysklerol | Atossisclerol | Atoxysclerol | Aetoxisclerol | Hydroxypolyethoxydodecane | Lubrol-PX | Lubrol PX | Polyoxyethylene 9-lauryl Ether | Ether, Polyoxyethylene 9-lauryl | Polyoxyethylene 9 lauryl Ether | Polyoxyethylene 9-lauryl Ethers
Chemical Information
Molecular Formula C30H62O10
CAS Registry Number 3055-99-0
SMILES CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.013--Not Available
Injection site thrombosis24.01.01.023; 12.07.03.028; 08.02.03.028--Not Available
Injection site warmth12.07.03.036; 08.02.03.036--Not Available
Loss of consciousness17.02.04.004--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Nausea07.01.07.0010.001144%
Neovascularisation24.03.02.011--Not Available
Pain08.01.08.0040.003717%
Pain in extremity15.03.04.0100.002287%
Palpitations02.01.02.003--
Paraesthesia17.02.06.0050.000572%
Pruritus23.03.12.0010.000858%
Pulmonary embolism24.01.06.001; 22.06.02.0010.000858%Not Available
Pulse absent13.14.04.0050.000572%Not Available
Pyrexia08.05.02.0030.000858%
Rash23.03.13.0010.001430%Not Available
Skin discolouration23.03.03.0050.004003%Not Available
Skin hyperpigmentation23.05.01.003--
Swelling08.01.03.0150.002859%Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.008--
Tenderness08.01.08.0050.000572%Not Available
Ulcer08.03.06.0010.000572%Not Available
Urticaria23.04.02.001; 10.01.06.0010.002001%
Vasculitis24.05.02.001; 10.02.02.006--
Vision blurred06.02.06.007; 17.17.01.0100.000572%
Contusion23.03.11.002; 15.03.01.008; 12.01.06.001; 24.07.06.0010.001430%
Deep vein thrombosis24.01.02.0030.002573%Not Available
Injection site discolouration08.02.03.038; 23.03.03.046; 12.07.03.038--Not Available
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Nodule08.03.05.0020.001144%Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages